POST Facilitation for Community Dwelling Older Adults (POST-RCT) (POST-RCT)

November 24, 2025 updated by: Alexia M. Torke, Indiana University

POST Facilitation for Community Dwelling Older Adults With and Without Dementia

We propose to study the effects of Physician Orders for Scope of Treatment (POST) Facilitation in a randomized controlled trial in a population of community dwelling older adults who qualify for POLST facilitation, including those with normal cognition and those with Alzheimer's Disease and Related Disorders.

Study Overview

Detailed Description

The POLST paradigm, which stands for Physician Orders for Life Sustaining Treatment, was developed to address inconsistencies between care received and patient and family wishes for treatment, with an aim to increase concordant care. The POLST paradigm is nationally recognized and implemented in a number of states under different names. In Indiana, for example, it is called "Physician Orders for Scope of Treatment" (POST). Because of this, all patient facing materials will refer to POST, however, we use the terms POST and POLST interchangeably in this proposal.

POLST affects delivery of medical interventions and improved concordance between patient preferences and care received.

Our specific aims are:

  1. To test the effect of high quality POLST Facilitation delivered in the home compared to attention control on:

    a.discordance between preferences for treatment and treatments received in the subsequent 12 months (primary outcome).

  2. To test the effect of POLST Facilitation on intermediate outcomes including:

    1. The proportion of patients with a completed POLST form in the electronic medical record within 3 months of POLST Facilitation
    2. Decision quality regarding ACP as measured by the Decisional Conflict Scale, the advance care planning (ACP) Engagement Survey,and the POLST knowledge survey
  3. To test the effect of a POLST Facilitation on secondary outcomes of cost and end-of-life care including:

    1. Receipt of life-sustaining interventions or hospice within the 30 days prior to death, for patients who die during the year after POLST Facilitation
    2. The psychological well-being (anxiety, depression,and post traumatic stress) of surrogate decision makers after the patient's death
    3. The cost effectiveness of POLST Facilitation for the prevention of ICU admissions and hospitalizations

Study Type

Interventional

Enrollment (Actual)

389

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • IU Health Methodist Hospital
      • Indianapolis, Indiana, United States, 46202
        • Eskenazi Health
      • Indianapolis, Indiana, United States, 46202
        • IU Health University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patients:

  • 65 or older
  • have decision making capacity OR a qualified surrogate decision maker
  • must meet one of the following index scores:

    • Gagne Mortality Index score of 7 or greater (30% mortality risk)
    • Medicare Criteria for Hospice Admission: Functional Assessment Staging Tool (FAST) Index (Advanced Alzheimer's disease and related dementia) 7c or higher plus one or more comorbid conditions.
    • Seattle Heart Failure Model (congestive heart failure): score conferring a one-year mortality risk of 30% or greater
    • Eastern Cooperative Oncology Group (ECOG) performance status (metastatic cancer): Patients with an impaired performance score (greater than zero)
    • Liu Comorbidity Index (End Stage Renal Disease): Patients with a score of 10 or greater
    • blood results (B), age (A), respiratory variables (airflow obstruction, exacerbations, smoking) (R) and comorbidities (C) (BARC) Index for chronic obstructive pulmonary disease (COPD): high risk group
    • Model for End Stage Liver Disease (MELD) Index
  • must be able to pass consent verification
  • must not be enrolled in hospice
  • must not have an acute illness
  • must give patient's provider opportunity to review the "surprise question" (e.g. would you be surprised if the patient died in the next year) to confirm anticipated mortality within the next year (14 days to respond)
  • must not have a POST form on file.

Exclusion criteria:

  • lack of a patient or surrogate decision maker who can participate in POLST facilitation (for non-decisional patients a health care representative (HCR) or designated power of attorney for health care (DPOA-HC) must enroll with them)
  • patients who are already enrolled in hospice
  • patients or surrogates who cannot pass consent verification
  • patients or surrogates who do not speak English
  • patients with a POST form on file
  • patients who are not community-dwelling

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Attention Control (Home Safety Evaluation)
A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
Experimental: Intervention (POST Facilitation)
A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form. The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
Other Names:
  • Respecting Choices Advanced Steps

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Discordance between treatment preferences and treatment received 12 months after POST Facilitation
Time Frame: Assessed 12 months from the date that the patient receives POST facilitation or home safety evaluation
Chart review and comparative statistics will be used to determine discordance between patient/family preferences and care received at the end of life.
Assessed 12 months from the date that the patient receives POST facilitation or home safety evaluation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients who have a completed POST form 3 months after receiving POST Facilitation
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Chart review and comparative statistics will be used to determine any correlations between intervention and completion of a POST form
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Decision conflict
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation

Decisional Conflict Scale (DCS)

The DCS is used to assess decision conflict

Scores range from 0 (no decisional conflict) to 100 (high decisional conflict) 0= 'strongly agree'; 1= 'agree'; 2= 'neither agree nor disagree'; 3= 'disagree'; 4= 'strongly disagree'.

TOTAL SCORE 16 items are: a) summed; b) divided by 16; and c) multiplied by 25 Other papers may present scores ranging from 1 [low decisional conflict] to 5 [high decisional conflict].

Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Effect of the intervention on cost and end of life care (EOL) for patients who die within 12 months of the intervention
Time Frame: Assessed by chart review 12 months from the date that the participant receives POST facilitation or a home safety evaluation
Will use comparative statistics to determine any correlations between intervention and EOL care (life sustaining treatments received and hospice enrollment within 30 days of death)
Assessed by chart review 12 months from the date that the participant receives POST facilitation or a home safety evaluation
Effect of the intervention on psychological well-being (anxiety)
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation

Generalized Anxiety Disorder- 7 (GAD-7) (7 item inventory of anxiety)- assesses subject's self-reported anxiety for the last two weeks.

Scores range from 0-21 0= 'Not at all'; 1= 'Several Days'; 2= 'More than half the days'; 3= 'Nearly every day' Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.

When used as a screening tool, further evaluation is recommended when the score is 10 or greater.

Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD.

Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Effect of the intervention on psychological well-being (depression)
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation

Patient Health Questionnaire-8 (PHQ-8: item inventory of depression)

Scores range from 0-24 *note that this scale is adapted from the PHQ-9, to remove the question about suicidal ideation.

0= 'Not at all'; 1= 'Several Days'; 2= 'More than half the days'; 3= 'Nearly every day' Higher scores indicate higher severity of depressive symptoms.

Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Effect of the intervention on psychological well-being (post traumatic stress)
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
(IES-R (Impact of Events Scale- Revised- inventory for PTSD) Scores range from 0-88 0= 'Not at all'; 1= 'A little bit'; 2= 'Moderately'; 3= 'Quite a bit'; 4= 'Extremely' The Impact of Event Scale-Revised (Weiss & Marmar, 1997) is a 22-item scale which is rated on a 0 (not at all) to 4 (extremely) scale with respect to how distressing each item has been during the past week. Scale scores are formed for the three subscales, which reflect intrusion (8 items), avoidance (8 items), and hyperarousal (6 items).
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Decision quality- ACP engagement
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Advance Care Planning (ACP) engagement survey
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
Decision quality- POLST Knowledge
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
POLST Knowledge Survey
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alexia M Torke, MD, MS, Regenstrief Institute, Indiana University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2020

Primary Completion (Actual)

July 29, 2025

Study Completion (Actual)

July 29, 2025

Study Registration Dates

First Submitted

August 24, 2019

First Submitted That Met QC Criteria

August 24, 2019

First Posted (Actual)

August 28, 2019

Study Record Updates

Last Update Posted (Actual)

November 26, 2025

Last Update Submitted That Met QC Criteria

November 24, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We will construct a de-identified data set that could be available to other researchers. Survey data, technical appendix and statistical code will be preserved and shared via the NIH-supported National Archive of Computerized Data on Aging's (NACDA) Open Aging Repository (OAR).

IPD Sharing Time Frame

One year after publication of all prespecified study outcomes.

IPD Sharing Access Criteria

The PI will review requests based on a brief description of the request, provided by the requestor.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Home Safety Evaluation

Subscribe